Structure-based non-canonical amino acid design to covalently crosslink an antibody-antigen complex

Jianqing Xu, Drew Tack, Randall A. Hughes, Andrew D. Ellington, Jeffrey J Gray

Research output: Contribution to journalArticle

Abstract

Engineering antibodies to utilize non-canonical amino acids (NCAA) should greatly expand the utility of an already important biological reagent. In particular, introducing crosslinking reagents into antibody complementarity determining regions (CDRs) should provide a means to covalently crosslink residues at the antibody-antigen interface. Unfortunately, finding the optimum position for crosslinking two proteins is often a matter of iterative guessing, even when the interface is known in atomic detail. Computer-aided antibody design can potentially greatly restrict the number of variants that must be explored in order to identify successful crosslinking sites. We have therefore used Rosetta to guide the introduction of an oxidizable crosslinking NCAA, l-3,4-dihydroxyphenylalanine (l-DOPA), into the CDRs of the anti-protective antigen scFv antibody M18, and have measured crosslinking to its cognate antigen, domain 4 of the anthrax protective antigen. Computed crosslinking distance, solvent accessibility, and interface energetics were three factors considered that could impact the efficiency of l-DOPA-mediated crosslinking. In the end, 10 variants were synthesized, and crosslinking efficiencies were generally 10% or higher, with the best variant crosslinking to 52% of the available antigen. The results suggest that computational analysis can be used in a pipeline for engineering crosslinking antibodies. The rules learned from l-DOPA crosslinking of antibodies may also be generalizable to the formation of other crosslinked interfaces and complexes.

Original languageEnglish (US)
Pages (from-to)215-222
Number of pages8
JournalJournal of Structural Biology
Volume185
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Antigen-Antibody Complex
Amino Acids
Dihydroxyphenylalanine
Antibodies
Complementarity Determining Regions
Antigens
Cross-Linking Reagents
Efficiency
Computer-Aided Design
Single-Chain Antibodies
Proteins

Keywords

  • Antibody
  • Binding affinity
  • Computer-aided design
  • Crosslinking
  • L-DOPA
  • Non-canonical amino acid
  • Rosetta
  • Structure-based design

ASJC Scopus subject areas

  • Structural Biology

Cite this

Structure-based non-canonical amino acid design to covalently crosslink an antibody-antigen complex. / Xu, Jianqing; Tack, Drew; Hughes, Randall A.; Ellington, Andrew D.; Gray, Jeffrey J.

In: Journal of Structural Biology, Vol. 185, No. 2, 02.2014, p. 215-222.

Research output: Contribution to journalArticle

Xu, Jianqing ; Tack, Drew ; Hughes, Randall A. ; Ellington, Andrew D. ; Gray, Jeffrey J. / Structure-based non-canonical amino acid design to covalently crosslink an antibody-antigen complex. In: Journal of Structural Biology. 2014 ; Vol. 185, No. 2. pp. 215-222.
@article{1026cc5ad7dc4ed79fb9d936904a956b,
title = "Structure-based non-canonical amino acid design to covalently crosslink an antibody-antigen complex",
abstract = "Engineering antibodies to utilize non-canonical amino acids (NCAA) should greatly expand the utility of an already important biological reagent. In particular, introducing crosslinking reagents into antibody complementarity determining regions (CDRs) should provide a means to covalently crosslink residues at the antibody-antigen interface. Unfortunately, finding the optimum position for crosslinking two proteins is often a matter of iterative guessing, even when the interface is known in atomic detail. Computer-aided antibody design can potentially greatly restrict the number of variants that must be explored in order to identify successful crosslinking sites. We have therefore used Rosetta to guide the introduction of an oxidizable crosslinking NCAA, l-3,4-dihydroxyphenylalanine (l-DOPA), into the CDRs of the anti-protective antigen scFv antibody M18, and have measured crosslinking to its cognate antigen, domain 4 of the anthrax protective antigen. Computed crosslinking distance, solvent accessibility, and interface energetics were three factors considered that could impact the efficiency of l-DOPA-mediated crosslinking. In the end, 10 variants were synthesized, and crosslinking efficiencies were generally 10{\%} or higher, with the best variant crosslinking to 52{\%} of the available antigen. The results suggest that computational analysis can be used in a pipeline for engineering crosslinking antibodies. The rules learned from l-DOPA crosslinking of antibodies may also be generalizable to the formation of other crosslinked interfaces and complexes.",
keywords = "Antibody, Binding affinity, Computer-aided design, Crosslinking, L-DOPA, Non-canonical amino acid, Rosetta, Structure-based design",
author = "Jianqing Xu and Drew Tack and Hughes, {Randall A.} and Ellington, {Andrew D.} and Gray, {Jeffrey J}",
year = "2014",
month = "2",
doi = "10.1016/j.jsb.2013.05.003",
language = "English (US)",
volume = "185",
pages = "215--222",
journal = "Journal of Structural Biology",
issn = "1047-8477",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Structure-based non-canonical amino acid design to covalently crosslink an antibody-antigen complex

AU - Xu, Jianqing

AU - Tack, Drew

AU - Hughes, Randall A.

AU - Ellington, Andrew D.

AU - Gray, Jeffrey J

PY - 2014/2

Y1 - 2014/2

N2 - Engineering antibodies to utilize non-canonical amino acids (NCAA) should greatly expand the utility of an already important biological reagent. In particular, introducing crosslinking reagents into antibody complementarity determining regions (CDRs) should provide a means to covalently crosslink residues at the antibody-antigen interface. Unfortunately, finding the optimum position for crosslinking two proteins is often a matter of iterative guessing, even when the interface is known in atomic detail. Computer-aided antibody design can potentially greatly restrict the number of variants that must be explored in order to identify successful crosslinking sites. We have therefore used Rosetta to guide the introduction of an oxidizable crosslinking NCAA, l-3,4-dihydroxyphenylalanine (l-DOPA), into the CDRs of the anti-protective antigen scFv antibody M18, and have measured crosslinking to its cognate antigen, domain 4 of the anthrax protective antigen. Computed crosslinking distance, solvent accessibility, and interface energetics were three factors considered that could impact the efficiency of l-DOPA-mediated crosslinking. In the end, 10 variants were synthesized, and crosslinking efficiencies were generally 10% or higher, with the best variant crosslinking to 52% of the available antigen. The results suggest that computational analysis can be used in a pipeline for engineering crosslinking antibodies. The rules learned from l-DOPA crosslinking of antibodies may also be generalizable to the formation of other crosslinked interfaces and complexes.

AB - Engineering antibodies to utilize non-canonical amino acids (NCAA) should greatly expand the utility of an already important biological reagent. In particular, introducing crosslinking reagents into antibody complementarity determining regions (CDRs) should provide a means to covalently crosslink residues at the antibody-antigen interface. Unfortunately, finding the optimum position for crosslinking two proteins is often a matter of iterative guessing, even when the interface is known in atomic detail. Computer-aided antibody design can potentially greatly restrict the number of variants that must be explored in order to identify successful crosslinking sites. We have therefore used Rosetta to guide the introduction of an oxidizable crosslinking NCAA, l-3,4-dihydroxyphenylalanine (l-DOPA), into the CDRs of the anti-protective antigen scFv antibody M18, and have measured crosslinking to its cognate antigen, domain 4 of the anthrax protective antigen. Computed crosslinking distance, solvent accessibility, and interface energetics were three factors considered that could impact the efficiency of l-DOPA-mediated crosslinking. In the end, 10 variants were synthesized, and crosslinking efficiencies were generally 10% or higher, with the best variant crosslinking to 52% of the available antigen. The results suggest that computational analysis can be used in a pipeline for engineering crosslinking antibodies. The rules learned from l-DOPA crosslinking of antibodies may also be generalizable to the formation of other crosslinked interfaces and complexes.

KW - Antibody

KW - Binding affinity

KW - Computer-aided design

KW - Crosslinking

KW - L-DOPA

KW - Non-canonical amino acid

KW - Rosetta

KW - Structure-based design

UR - http://www.scopus.com/inward/record.url?scp=84894965507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894965507&partnerID=8YFLogxK

U2 - 10.1016/j.jsb.2013.05.003

DO - 10.1016/j.jsb.2013.05.003

M3 - Article

C2 - 23680795

AN - SCOPUS:84894965507

VL - 185

SP - 215

EP - 222

JO - Journal of Structural Biology

JF - Journal of Structural Biology

SN - 1047-8477

IS - 2

ER -